For dates of service before April 1, 2023: J0610 was valid
It was a setback, but as it often happens in science, it was not the end of the road for AOD-9604, paving the way for a new and unexpected chapter in its story
Whilst some patients would prefer injections to skin patches or nasal sprays to sub-lingual tablets or sprays others might, and this already happens in a few cases, they might prefer daily oral tablets
Here is what that looks like in practice: Appetite regulation: Tirzepatide activates GLP-1 and GIP receptors that signal fullness, reduce cravings, and slow gastric emptying so you feel satisfied with smaller portions
Its vital to know how these differ from a medically prescribed injection
Does not stimulate IGF-1, potentially safer for joint applications